Testing afimkibart for children with Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh at least 22 pounds (10 kilograms)
- Have Crohn's disease confirmed by a scope exam of the intestines
- Have disease that is moderately to severely active, based on a specific symptom score and a scope score
- Have tried at least one other treatment (like steroids or stronger medicines) that did not work well enough or caused side effects
- Not have other conditions like ulcerative colitis, fistulas, or an abscess in the belly area
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
This study gives tulisokibart to people who already took part in an earlier trial for Crohn's disease or ulcerative colitis and are still benefiting from it. The goal is to see how safe and effective the medicine is over a longer period.
This study tests a new drug called afimkibart in children with moderate to severe ulcerative colitis who haven't responded well to other treatments. It aims to see how well the drug works and if it's safe for children.
This trial is testing a new medication called afimkibart (RO7790121) for people with moderate to severe ulcerative colitis. It aims to see if this treatment can help reduce inflammation and improve symptoms in people who haven't had success with other therapies.
This study looks at how afimkibart affects the way your body processes certain other medicines. It is for people with moderate to severe ulcerative colitis and helps researchers understand how to use this treatment safely.
Hear when a new Moderately to Severely Active Crohns Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.